Skip to main content

Advertisement

SpringerLink
Log in

Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Recent data suggest that atherosclerotic disease is increased in patients with idiopathic inflammatory myositis (IIM) and that dyslipidemia is a significant risk factor for cardiovascular events. Lipid-lowering agents may be associated with myopathic side effects. The current work evaluates the use of lipid-lowering therapy in patients with IIM treated by IIM specialists belonging to the International Myositis Assessment and Clinical Studies (IMACS) Group. The IMACS Group is a multidisciplinary coalition of experts with significant interest and experience in IIM. IMACS members were asked to complete an 18-item online survey detailing their clinical practice on monitoring and treating hypercholesterolemia in IIM patients. Specific questions regarding the types of lipid-lowering therapies used in IIM patients and any side effects associated with treatment were asked. Sixty-three IMACS members representing 23 countries and a minimum of 1,641 IIM patients participated in the online survey. Seventy-six percent of these specialists treating adult IIM patients use lipid-lowering therapies in their patients. HMG co-enzymeA reductase inhibitors (statins) were the most commonly used agents (93 %). Thirty-six cases of worsening myositis associated with statin use were reported in over 300 patients using lipid-lowering therapies. Seven of eight responders who reported worsening in myositis with lipid-lowering therapies reported cases in which the myositis improved after holding therapy. This survey suggests that statins are commonly used by physicians specializing in the treatment of patients with IIM and that some myositis patients worsen with statin use and may improve on dechallenge. More research regarding the safety of lipid-lowering agents in patients with IIM is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46(10):1560–1565

    Article  CAS  Google Scholar 

  2. Norby GE, Holme I, Fellstrom B, Jardine A, Cole E, Abedini S et al (2009) Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis Rheum 60(4):1060–1064

    Article  PubMed  CAS  Google Scholar 

  3. Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V et al (2007) A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 27(11):1071–1077

    Article  PubMed  CAS  Google Scholar 

  4. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM et al (2007) Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 34(7):1459–1464

    PubMed  CAS  Google Scholar 

  5. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363(9426):2015–2021

    Article  PubMed  CAS  Google Scholar 

  6. Lundberg IE, Forbess CJ (2008) Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 26(5 Suppl 51):S109–S114

    PubMed  CAS  Google Scholar 

  7. Tisseverasinghe A, Bernatsky S, Pineau CA (2008) Thromboembolic Arterial events in idiopathic inflammatory myopathy. Arthritis Rheum 58(9):S173, Ref Type: Abstract

    Google Scholar 

  8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333(20):1301–1307

    Article  PubMed  CAS  Google Scholar 

  9. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373(9670):1175–1182

    Article  PubMed  CAS  Google Scholar 

  10. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H et al (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170(3):1524–1530

    PubMed  CAS  Google Scholar 

  11. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6(12):1399–1402

    Article  PubMed  CAS  Google Scholar 

  12. Phillips PS, Haas RH (2008) Statin myopathy as a metabolic muscle disease. Expert Rev Cardiovasc Ther 6(7):971–978

    Article  PubMed  CAS  Google Scholar 

  13. Klopstock T (2008) Drug-induced myopathies. Curr Opin Neurol 21(5):590–595

    Article  PubMed  Google Scholar 

  14. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al (2008) SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359(8):789–799

    Article  PubMed  CAS  Google Scholar 

  15. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR et al (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63(3):713–721

    Article  PubMed  CAS  Google Scholar 

  16. Padala S, Thompson PD (2011) Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis. doi:10.1016/j.atherosclerosis.2011.11.005

  17. Harper CR, Jacobson TA (2010) Evidence-based management of statin myopathy. Curr Atheroscler Rep 12(5):322–330

    Article  PubMed  CAS  Google Scholar 

  18. Baer AN, Wortmann RL (2007) Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 19(1):67–73

    PubMed  CAS  Google Scholar 

  19. Davidson MH, Armani A, McKenney JM, Jacobson TA (2007) Safety considerations with fibrate therapy. Am J Cardiol 99(6A):3C–18C

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 1000 Veteran Avenue Room 32-59, Los Angeles, CA, 90095-1670, USA

    Christina Charles-Schoeman, Sogol S. Amjadi & Harold E. Paulus

Authors
  1. Christina Charles-Schoeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sogol S. Amjadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harold E. Paulus
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the International Myositis Assessment and Clinical Studies Group

Corresponding author

Correspondence to Christina Charles-Schoeman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Charles-Schoeman, C., Amjadi, S.S., Paulus, H.E. et al. Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey. Clin Rheumatol 31, 1163–1168 (2012). https://doi.org/10.1007/s10067-012-1986-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-1986-4

Keywords

Search

Navigation